Cargando…

Apixaban anti-Xa level monitoring in treatment of acute upper extremity deep vein thrombosis for patient on chronic hemodialysis: a case report

BACKGROUND: Patients on dialysis are at higher risk of major bleeding and recurrent thrombosis creating acute venous thromboembolism (VTE) treatment challenges. DOACs represent an interesting option but there are concerns of bioaccumulation and increased bleeding risk. Anti-Xa trough levels may be u...

Descripción completa

Detalles Bibliográficos
Autores principales:	Roberge, Guillaume, Wells, Philip Stephen
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Case Report
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8017605/ https://www.ncbi.nlm.nih.gov/pubmed/33794913 http://dx.doi.org/10.1186/s12959-021-00277-8

Ejemplares similares

Upper extremity deep vein thrombosis
por: Saseedharan, Sanjith, et al.
Publicado: (2012)

The new factor Xa inhibitor: Apixaban
por: Bhanwra, Sangeeta, et al.
Publicado: (2014)

Systemic thrombolysis in the upper extremity deep vein thrombosis
por: Sadeghi, Roxana, et al.
Publicado: (2011)

Upper extremity deep vein thrombosis with tourniquet use
por: Desai, Karan, et al.
Publicado: (2014)

Upper extremity deep vein thrombosis: An intensivist’s perspective
por: Singh, Omender, et al.
Publicado: (2023)

Risk and Prognosis of Upper Extremity Deep Vein Thrombosis
por: Endo, Yusuke, et al.
Publicado: (2023)

Antiphospholipid antibodies in patients with upper-extremity deep vein thrombosis
por: Nikolova-Vlahova, Milena K., et al.
Publicado: (2015)

Diagnostic and Therapeutic Management of Upper Extremity Deep Vein Thrombosis
por: Bosch, Floris T. M., et al.
Publicado: (2020)

Thymoma Causing Bilateral Upper Extremity Deep Vein Thrombosis
por: Bui, Hoang, et al.
Publicado: (2020)

Idiopathic pulmonary vein thrombosis treated with apixaban
por: Ngo, Dallis, et al.
Publicado: (2021)

Clinical Use of Anti-Xa Monitoring in Malignancy-Associated Thrombosis
por: Yentz, Sarah, et al.
Publicado: (2015)

Studies in upper extremity deep vein thrombosis: Addressing the knowledge gaps
por: Lazo‐Langner, Alejandro
Publicado: (2019)

Recurrence of Upper Extremity Deep Vein Thrombosis Secondary to COVID-19
por: Parekh, Yesha H., et al.
Publicado: (2021)

Idiopathic upper extremity deep vein thrombosis: A systematic review
por: Yuen, Hiu Lam Agnes, et al.
Publicado: (2022)

A STROBE cohort study of 755 deep and superficial upper-extremity vein thrombosis
por: Ploton, Gaetan, et al.
Publicado: (2020)

Isolated Radial Vein Thrombosis: Upper Extremity Deep Vein Thrombosis in a Patient With COVID-19 Infection
por: Ramalingam, Sathishkumar, et al.
Publicado: (2021)

Apixaban for the prophylaxis and treatment of deep vein thrombosis and pulmonary embolism: an evidence-based review
por: Mandernach, Molly W, et al.
Publicado: (2015)

Deep vein thrombosis of upper extremities due to reactive thrombocytosis in septic patients
por: Mishra, Shakti Bedanta, et al.
Publicado: (2014)

Treatment with direct oral anticoagulants in patients with upper extremity deep vein thrombosis
por: Montiel, Francisco Sánchez, et al.
Publicado: (2017)

Upper-extremity Deep Vein Thrombosis Complicating Apheresis in a Healthy Donor
por: Haba, Yuichiro, et al.
Publicado: (2017)

Incidence of Upper Extremity Deep Vein Thrombosis in Acute Leukemia and Effect on Mortality
por: Poh, Christina, et al.
Publicado: (2020)

Incidence of upper extremity deep vein thrombosis in the retrosternal reconstruction after esophagectomy
por: Yamada, Leo, et al.
Publicado: (2022)

Clinical implication of monitoring rivaroxaban and apixaban by using anti-factor Xa assay in patients with non-valvular atrial fibrillation
por: Ikeda, Kozue, et al.
Publicado: (2016)

Asymptomatic deep vein thrombosis in critically ill COVID-19 patients despite therapeutic levels of anti-Xa activity
por: Torres-Machorro, Adriana, et al.
Publicado: (2020)

Predictive factors of venous recanalization in upper-extremity vein thrombosis
por: Ploton, Gaëtan, et al.
Publicado: (2021)

Apixaban for Routine Management of Upper Extremity Deep Venous Thrombosis (ARM‐DVT): Methods of a prospective single‐arm management study
por: Woller, Scott C., et al.
Publicado: (2019)

A case report on 2 unique presentations of upper extremity deep vein thrombosis
por: Yunce, Muharrem, et al.
Publicado: (2018)

Upper Extremity Deep Vein Thrombosis as the Tip of the Iceberg: Case Report and Review of Literature
por: Fontes, Joana, et al.
Publicado: (2023)

Effect of famotidine on the pharmacokinetics of apixaban, an oral direct factor Xa inhibitor
por: Upreti, Vijay V, et al.
Publicado: (2013)

Prolonged Fasting as a Cause of Deep Vein Thrombosis: A Case Report
por: Roberge, Guillaume, et al.
Publicado: (2023)

Development of New Deep Venous Thrombosis While on Apixaban
por: Sharma, Munish, et al.
Publicado: (2017)

The Laterality of Deep Vein Thrombosis in the Pelvic and Lower Extremity Veins
por: Shin, Ha Song, et al.
Publicado: (2014)

Apixaban and rivaroxaban anti-Xa level utilization and associated bleeding events within an academic health system
por: Jakowenko, Nicholas, et al.
Publicado: (2020)

Assessment of Anti‐Xa activity in patients receiving concomitant apixaban with strong p‐glycoprotein inhibitors and statins
por: Milner, Erin, et al.
Publicado: (2022)

Upper extremity deep vein thrombosis in a 25 year old apparently healthy man
por: Girma, Fitsum
Publicado: (2010)

Detection of upper extremity deep vein thrombosis by magnetic resonance non‐contrast thrombus imaging
por: van Dam, Lisette F., et al.
Publicado: (2021)

Upper Extremity Deep Vein Thrombosis After Botulinum Toxin Injection: A Case Report
por: Lim, Nana, et al.
Publicado: (2021)

P1678: ENDOVASCULAR TREATMENT FOR UPPER AND LOWER EXTREMITY DEEP VEIN THROMBOSIS, CASE REPORTS
por: Casamayor Garcia, A., et al.
Publicado: (2022)

D‐dimer level for ruling out peripherally inserted central catheter‐associated upper extremity deep vein thrombosis and superficial vein thrombosis
por: Liu, Wanli, et al.
Publicado: (2021)

Preclinical discovery of apixaban, a direct and orally bioavailable factor Xa inhibitor
por: Wong, Pancras C., et al.
Publicado: (2011)

Cannot write session to /tmp/vufind_sessions/sess_gupal7gk0pgsu6bihchkprp041